Assessment of the Effect of BI 201335 on the QT Interval in Healthy Female and Male Subjects

Inclusion Criteria: * Healthy caucasian males and females, 18 to 50 years of age * Body mass index (BMI) ranging from 18.5 to 29.9 kg/m2 (BMI calculation: weight in kilograms divided by the square of height in meters) * Signed written informed consent prior to admission to the study in accordance with Good Clinical Practice and the local legislation Exclusion Criteria: * Any finding of the medical examination (including blood pressure, pulse rate and electrocardiogram (ECG)) deviating from normal and of clinical relevance * Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders * Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders * History of orthostatic hypotension, fainting spells or blackouts * Chronic or relevant acute infections * History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator * Intake of drugs with a long half-life (\> 24 hours) within at least one month or less than 10 half-lives of the respective drug before enrolment in the study or during the study * Use of any drugs which might influence the results of the trial up to 7 days prior to enrolment in the study or during the study * Participation in another trial with an investigational drug (≤ 30 days prior to administration or during the trial) * Heavy smoker (\> 10 cigarettes or \> 3 cigars of \> 3 pipes/day) * Inability to refrain from smoking on trial days * Alcohol abuse (\> 60 g/day) * Drug abuse * Blood donation (≥ 100 mL within four weeks prior to administration or during the trial) * Any deviation of a laboratory value that is considered to be of clinical relevance * Excessive physical activities within the last week before the trial or during the trial * Hypersensitivity to BI 201335, moxifloxacin or related drugs of these classes * Homozygous genotype status for "Gilbert" polymorphisms (Uridine diphosphate (UDP)-glucuronosyl transferase 1A1 (UGT1A1)\*28, \*60) * Heart rate at screening of \> 85 bpm or \< 40 bpm * Any screening ECG value outside of the reference range of clinical relevance including, but not limited to pulse rate (PR) interval \> 220 ms, QRS interval \> 115 ms, QTcB (QT interval, corrected for heart rate according to Bazett's formula) \> 470 ms, or QT (uncorrected) \> 470 ms * For Female subjects * Pregnancy * Positive pregnancy test * No adequate contraception (adequate contraception e.g. sterilisation, intrauterine pressure , oral contraceptives). Females, who are not surgically sterile will be asked to additionally use barrier contraception methods (e.g. condom, diaphragm with spermicide) * Inability to maintain this adequate contraception during the whole study period from the time of screening until one month after the last intake * Lactation period